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Shanghai, China and 5) Pennsylvania State University College of Medicine and Hershey Medical Center, Hershey, PA, USAAbstractNucleotide sequencing of the phylogenetically informative region of NS5B remains the gold standard for hepatitis C virus (HCV) genotyping. Here
we developed a newmethodology for sequencing newNS5B regions to increase the accuracy and sensitivity of HCV genotyping and subtyping. The
eight new primerswere identiﬁed by scanning the full-lengthNS5B regions from1127HCVgenomic sequences found inHCVdatabases. The ability
of each pair of primers to amplify HCV subtypes was scored, and the new primers were able to amplify the NS5B region better than the previously
used primers, therefore more accurately subtyping HCV strains. Sequencing the DNA ampliﬁed by the new primer pairs can speciﬁcally and
correctly detect the ﬁve standard HCV subtypes (1a, 2a, 3b, 6a and 1b). We further examined patient samples and found that the new primers
were able to identify HCV subtypes in clinical samples with high sensitivity. This method was able to detect all subtypes of HCV in 567 clinical
samples. Importantly, three novel HCV subtypes (1b-2a, 1b-2k and 6d-6k) were identiﬁed in the samples, which have not been previous
reported in China. In conclusion, sequencing the NS5B region ampliﬁed by the new NS5B primers is a more reliable method of HCV
genotyping and a more sensitive diagnostic tool than sequencing using the previously described primers, and could identify new HCV subtypes.
Our research is useful for clinical diagnosis, guidance of clinical treatment, management of clinical patients, and studies on the epidemiology of HCV.
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Y.-Q. Tong, B. Liu and H. Liu are contributed equally to this work.IntroductionHepatitis C virus (HCV) is a blood-borne pathogen that is
spread through blood and other body ﬂuids [1,2]. It is amongMicrobiol Infect 2015; 21: 874.e9–874.e21
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.05.034the most common viruses infecting the liver; every year, 3–4
million people are infected by HCV [3]. HCV infection is only
cleared in approximately 25% of the cases, leaving about 150
million people chronically infected [4]. Each year more than 350
000 people die from HCV-related liver diseases, such as chronic
liver disease, cirrhosis and hepatocellular carcinoma (HCC) [5].
Hepatitis C virus is a positive-sense RNA virus with a
genome of about 9400 bases, which encodes a single poly-
protein that is cleaved into four structural proteins (Core,
Envelope 1 and 2, and p7) and six non-structural proteins
named NS2–NS5B [6]. HCV is divided into six distinct geno-
types throughout the world with multiple subtypes in each
genotype class [7–9]. Variations in the HCV genome are used
to classify the virus into genotypes [10]. Accurate classiﬁcation
of genotypes and subtypes of HCV is important for correctious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Tong et al. Accurate genotyping of HCV through new NS5B regions 874.e10stratiﬁcation of groups in clinical trials and accurate analysis of
data related to efﬁcacy and resistance of new HCV drugs. It is
also essential for the implementation of therapeutic pro-
cedures, the production of effective vaccines, the improvement
of diagnostic tests [11–13], and a better understanding of the
epidemiological and physical features of the virus [14].
Importantly, the tendency for development of HCC is
increased among people with chronic HCV infection [15,16].
Also, the rate of HCV infection is unexpectedly high in the
Asian population, and HCV infection at an older age may give a
greater risk of HCC [17]. Therefore, the development of a
more sensitive and accurate methodology for HCV genotyping
would have a signiﬁcant impact on further understanding the
correlation of HCV genotypes with evolution of severe liver
diseases, particularly HCC.
Many genotyping methods targeting different regions of the
HCV genome have been developed, such as restriction fragment
length polymorphism, line probe assay, TaqMan PCR, liquid
microarray, sequencing, solid-phase electrochemical array
[18–21]. Sequencing of a genome region divergent enough to
discriminate genotypes and subtypes, such as HCV NS5B, core
and envelope regions, is considered to be the most accurate
method [22,23]. This method of genotyping the HCV 5’-un-
translated region gives sufﬁcient information for clinical pur-
poses, where the determination of the subtype is not essential.
NS5B genotyping methods are more reliable for subtype
determination [24,25]. Direct sequencing of a portion of the
NS5B gene followed by phylogenetic analysis is the standard
method for identifying HCV genotypes and subtypes [26]. To
date, sequencing the NS5B gene to analyse HCV genotype and
subtype is considered the most reliable method; however, most
reports have used a partial short NS5B fragment to genotype
HCV [27,28], and such a classiﬁcation has certain drawbacks
such as low accuracy and a limit to the number of subtypes it can
identify. In this study, all nucleic acid sequences from the HCV
database were used to predict potential primers located in the
NS5B region by PRIMER 5.0, and new fragments of the NS5B gene
were ampliﬁed by the resulting primers and sequenced for HCV
genotyping. The primers can correctly amplify the known nucleic
acid sequences of standard HCV strains. HCV was also accu-
rately detected by these primers in patient samples. Results
demonstrate that this method can accurately detect the subtypes
of all HCV patient samples with high sensitivity.Materials and methodsEthics statement
This study was approved by the Institutional Review Board of
Renmin Hospital, Wuhan University School of Medicine. AClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infwritten informed consent was obtained from each participant in
accordance with the Renmin Hospital of Wuhan University
Ethics Committee.
HCV sequence databases and PCR primer design
Hepatitis C virus sequence databases (http://hcv.lanl.gov) were
downloaded from the genome databases of the University of
Alabama at Birmingham (ftp://ftp.genome.uab.edu/vbrc). All 1127
nucleotide sequences of HCV NS5B from the database were
clustered with MEGA 5.0 software. The clustered sequences of
NS5B regionwere used to search all possible forward primers and
reverse primers with PRIMER 5.0. Next, possible matching pairs of
primers were searched in all resulting primers. If the pair of
primers was able to hybridize to the sequence and met the re-
quirements of common primer design, we determined if the pair
of primers could amplify the fragment of the NS5B region. With
these strict criteria, the best primers were identiﬁed. Then, we
examined whether each pair of primers matches the corre-
sponding site in each NS5B region from all 1127 HCV sequences
by computing and calculated the ratio of each pair of primers for
each HCV subtype in the 1127 HCV sequences and the sensitivity
for ampliﬁcation. As control, one pair of the reported primerswas
also used for this analysis. Then, we did phylogenetic analysis of all
the ampliﬁed NS5B sequences by the pairs of primers and
compared that to the reported pair of primers.
Patients and plasma preparations
A total of 567 samples of 3–5 mL EDTA-anticoagulated pe-
ripheral blood were obtained from individuals with HCV in-
fections conﬁrmed by quantitative real-time RT-PCR before
treatment in the Department of Infectious Diseases, Renmin
Hospital of Wuhan University. The HCV RNA titres of all pa-
tients in this cohort were >103 IU/mL in the peripheral blood
with the conventional PCR ampliﬁcation method. For HCV
RNA titres of the patients <103 IU/mL, a more sensitive
method is required. We developed a nested PCR method using
universal primers, which can detect HCV RNA titres in 80 IU/
mL (data not shown). The HCV patients included patients with
acute hepatitis C, chronic hepatitis C, hepatitis C cirrhosis and
HCV acute exacerbation with no anti-viral treatment given
while they received HCV genotyping testing. The patients’ ages
ranged from 21 to 65 years (median 41.3 years). All samples
were centrifuged for 5 min at 3000 g, and the supernatants
were collected and stored at –70°. Five HCV standard strains
including HCV 1a, 2a, 3b, 6a and 1b were purchased from the
Institute of Virology, Wuhan University.
HCV RNA extraction
Viral RNA was extracted from plasma using the Viral RNA Mini
Spin Kit following the manufacturer’s instructions (Qiagen,ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
TABLE 1. The predicted primers for amplifying NS5B gene
fragments
Primer
name Primer sequence (50 to 30)
Location
(nucleotide)
F1 TTAACCACATCMRCTCCGTGTG 347–368
F2 ACACCCGCTGYTTYGACTC 659–677
F3 GCCTTCACGGARGCYATG 1012–1029
F4 CATGCCTCAGRAARCTTGG 1460–1478
R1 GTCAAAGCAGCGGGTRTCRTA 675–655
R2 GTACCTGGTCATAGCYTCCGTRAA 1038–1015
R3 GGGACCCCAAGYTTYCTGAG 1484–1465
R4 GCCGGCATTGGAGTGAGYYT 1622–1603
Degenerate base symbol: M, A and C; R, A and G; Y, C and T.
874.e11 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIHilden, Germany). Brieﬂy, the plasma volume was adjusted based
on viral load, i.e. 140 μL for HCV RNA5000 IU/mL and 280 μL
for HCV RNA <5000 IU/mL, and mixed with protease K
(40–120 μL) and AVL buffer (560–1120 μL) supplemented with
5.6–11.2 μg of carrier RNA (tRNA). The mixture was incubated
for 10 min at room temperature, and absolute ethanol
(560–1120 μL) was added to each sample and mixed by pulse-
vortexing for 15 s. The mixture was then loaded onto a mini
column and centrifuged at 6000 g. Subsequently, the mini column
was washed with AW1 buffer (500 μL) and AW2 buffer (500 μL),
respectively with centrifugation at 6000 g for 1 min. A second
wash with AW2 buffer (500 μL) was carried out with centrifu-
gation at 20 000 g for 3 min, and the column was dried with full
speed centrifugation for 1 min. The RNA was eluted by loading
50 μL of Buffer AVE onto each column, incubating for 1 min at
room temperature and centrifuging at 6000 g for 1 min. The
elution was repeated once to increase the yield. Finally, a total of
50 μL viral RNA was isolated from 140–280 μL of plasma.
cDNA synthesis
Complementary DNA was synthesized with the Thermo Sci-
entiﬁc RevertAid First Strand cDNA Synthesis Kit (Thermo
Fisher Scientiﬁc Inc., Waltham, MA, USA) from HCV RNA
following the manufacturer’s instructions. Brieﬂy, HCV RNA
was diluted 1:2 or 1:4 based on the viral load, i.e. 1:2 for HCV
RNA <5000 IU/mL and 1:4 for HCV RNA 5000 IU/mL, and
mixed with a total RT reaction volume of 20 μL composed of
1 μL of a random hexamer primer, 200 units of RevertAid M-
MuLV reverse transcriptase, 20 units of RiboLock RNase in-
hibitor, 4 μL of 5× reaction buffer, and 4 μL of 10 mM dNTP
mix. The RT reaction was carried out in a thermocycler with
the following conditions: 25°C for 5 min, 65°C for 5 min, 42°C
for 60 min, and 70°C for 5 min.
Ampliﬁcation of the HCV NS5B gene fragments by
PCR
The HCV cDNA template was used for the PCR ampliﬁcation,
and the PCR was performed as follows: 94°C for 3 min; 94°C
for 30 s, 56°C for 40 s, 72°C for 60 s, 35 cycles; 72°C for
10 min. The primers were selected in the same range of
annealing temperature as far as possible. The average Tm for all
selected primers was 56–60°C. Multiple pre-experiments with
different annual temperature from 54°C to 62°C were per-
formed, and the best annealing temperature was ﬁnally deﬁned
as 56°C, which could efﬁciently amplify all the fragment with
only slightly reduction of efﬁciency rate for F1, R4, F3 and R4.
The resulting PCR products were electrophoresed on a1.2%
agarose gel for gel puriﬁcation and documented by imaging. The
primers for amplifying NS5B gene fragments are shown in
Table 1. The conserved regions of 30 non-coding region of HCVClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwere used as control, which was ampliﬁed with forward primer
50-GCGGAACCGGTGAGTACA-30 and reverse primer 50-
CCTATCAGGCAGTACCACAAGG-30.
DNA puriﬁcation and sequencing
The gel-puriﬁed PCR products were used for sequencing with
the dideoxynucleotide chain termination method with the ABI
PRISM®BigDye Terminator Cycle Sequencing Reaction Kit
(Applied Biosystems, Foster City, CA, USA). Sequence analysis
was performed with the ABITM3130 Genetic Analyzer
(Applied Biosystems).
Phylogenetic analysis
All nucleotide sequences from HCV strains were aligned using
CLUSTALW 2.0 software with a reference panel of reported
sequences available in the HCV sequence database (http://hcv.
lanl.gov/content/hcv-db/index) provided by the Los Alamos
National Laboratory. Pairwise evolutionary distance matrices
for the NS5B nucleotide sequences were computed using the p-
distance algorithm of the MEGA software package (version 5.2,
2012; Pennsylvania State University, University Park, PA, USA).
Sequence distance matrices were analysed with conventional
statistical software (SYSTAT, v13.0; Systat Software, Inc., Point
Richmond, CA, USA) using ﬁles derived from MEGA distance
tables. For NS5B sequences, a p-distance of 0.12 was found to
delineate strains of the same subtype and strains of a different
subtype. Phylogenetic analysis was performed with the MEGA
software package using the p-distance algorithm for distance
determination and the neighbour-joining method for tree
drawing. The reliability of phylogenetic classiﬁcation was eval-
uated by a 1000-replication bootstrap test using the same
software package. Genotyping was performed using the
nomenclature deﬁned by Simmonds et al. [29].
Statistical analysis
The distribution of HCV genotypes was compared using chi-
square test and Fisher test. Differences were considered to
be statistically signiﬁcant when p < 0.05.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
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The HCV sequence databases (http://hcv.lanl.gov) were
searched for different subtypes of HCV genome. A total of
1127 HCV genome nucleic acid sequences were identiﬁed. As
reference, we ﬁrst analysed the distribution of the HCV sub-
types in the database, which is shown in Fig. 1a and the number
of each subtype is shown in Fig. 1b. From these data, we foundFIG. 1. Analysis of the hepatitis C virus (HCV) type and subtype from Viral B
subtypes in 1127 HCV sequences as shown on a pie chart (a) and numbers of e
analysis of the NS5B genomic region of HCV G1 strains. Genetic distance was
was constructed using the neighbour joining method. The phylogenetic analys
(c) to indicate full-length NS5B could clearly distinguish the subtypes of the H
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infthat the main genotypes among these sequences were HCV
1a,1b, 2b and 4a (Fig. 1a), which respectively accounted for
38.86% (438/1127), 29.72% (335/1127), 2.22% (25/1127) and
1.69% (19/1127) (Fig. 1b). Also there were variants, such as
HCV VAR1a, VAR1b and VAR2a (Fig. 1a), which respectively
accounted for 2.57% (29/1127), 7.72% (87/1127) and 3.99%
(45/1127) (Fig. 1b). Then, we used all nucleic acid sequences in
the NS5B region (full-length sequence of NS5B) to perform the
phylogenetic analysis for subtyping the 1127 HCV sequences.
The subtypes of the 1127 HCV sequences analysed with full-ioinformatics Resource Centre (a, b) the distribution frequency of HCV
ach subtypes as shown (b) in all the HCV sequences. (c–e) Phylogenetic
estimated by the Kimura two-parameter model, and a phylogenetic tree
es of the HCV type 3 (d) and HCV type 5 (e) are further enlarged from
CV.
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
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reference subtypes for each of the 1127 HCV sequences, and
the phylogenetic tree generated with a full-length sequence of
the NS5B region was the same as that of the referenced one
(Fig. 1c). The two regions of the phylogenetic tree enlarged
from Fig. 1c, clearly showed the subtypes of HCV 5 and HCV 3,
which is also same as that in the reference database (Fig. 1d, e).
These data indicate that the full-length sequence of the NS5B
region can correctly classify the subtypes of the HCV.
Furthermore, we analysed the genotypes using the HCV
sequences available not only in the above database (http://hcv.
lanl.gov) but also the NCBI database (http://www.ncbi.nlm.nih.
gov/projects/genotyping), which contains 32 HCV subtypes
including Subtype 1a (AF009606, AF011751, AF271632), Sub-
type 1b (D90208, AB049088, AF356827, AF139594), Subtype
1c (D14853, AY051292), Subtype 2a (D00944, AF169004,
AB047639, AB047641), Subtype 2b (D10988, AF238486,
AB030907, AY232730), Subtype 2c (D50409), Subtype 2i
(DQ155561), Subtype 2k (AB031663), Subtype 3a (D17763,
D28917, AF046866), Subtype 3b (D49374), Subtype 3k
(D63821), Subtype 4a (Y11604), Subtype 5a (Y13184,
AF064490), Subtype 6a (Y12083), Subtype 6b (D84262), Sub-
type 6d (D84263), Subtype 6g (D63822), Subtype 6h (D84265),
and Subtype 6k (D84264).
Phylogenetic analysis was performed to evaluate the genetic
relatedness of the 32 sequences in the NCBI HCV database
with the reported nucleic acid sequence from 8370 to 8708 or
8323 to 8638 in the NS5B region. The data showed that analysis
with the standard NS5B region mistakenly clustered subtype 5
into subtype 1, and clustered subtype 4 and subtype 5 together
(Fig. 2a). We also carried out the phylogenetic analysis with the
full-length sequence of the NS5B region and found subtypes 4
and 1 or subtypes 5 and 3 were clustered together but clearly
distinct (Fig. 2b), which is consistent with the data analysed with
the full-length sequence of NS5B region in 1127 HCV se-
quences as shown in Fig. 2c. Taken together, these analyses
indicate that subtyping with the full-length sequence of NS5B
could accurately distinguish the subtypes in both databases but
had less accuracy if using the reported partial NS5B region for
HCV genotyping. These analyses also suggested that sequencing
the full-length NS5B region was more accurate for HCV
subtyping.
Primers designed to cover the full-length of NS5B
region in all HCV sequences in the database
Each base in the NS5B region of the 1127 HCV sequences was
scanned with PRIMER 5.0 software to check suitable primers. The
base in the primer population was endowed with increasing
weight, which was transformed into image grey-scale. A region
with deep colour represents the high PCR ampliﬁcation abilityClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectacross the whole HCV population (Fig. 3A,a,b). A threshold was
set for clear image display and pixels less than the threshold
(500 dpi) was set as white colour. The oligos sequence must be
the same as that of the NS5B sequence or has up to two similar
oligonucleotides but these similar nucleotides must not be at
the 30 end. All of the 1127 NS5B sequences were initially
scanned to calculate the likelihood of each primer pair ampli-
fying the corresponding NS5B genotype, and were subsequently
screened for appropriate primer pairs with high efﬁciency for
common genotypes and high sensitivity for rare genotypes in
the detection (shown as red boxes in Fig. 3a,b). Based on these
criteria, eight primers were identiﬁed (Fig. 3c and Table 1),
which are able to amplify the region from site 347 to 1603 of
NS5B in almost all 1127 HCV subtypes. We also found that all
the ampliﬁcation products of the eight primers are located in
the red zones (high intensity, cover more HCV sequences) on
Fig. 3a,b. These analyses suggest that the eight primers have high
efﬁciency and sensitivity for ampliﬁcation.
Next, all possible pairs of the eight primers (ten pairs) were
used to examine their sensitivity in amplifying the fragments of
the NS5B gene region. The ampliﬁcation sensitivity of each
primer pair in detecting HCV genotypes and subtypes was
evaluated by blasting the HCV database. Overall, the pairs of
the eight primers could successfully amplify 1117 fragments out
of 1127 NS5B, except for seven HCV 1b, one HCV 2b, one
HCV 3a and HCV 7 with 88.73–96.45% sensitivity for ampli-
ﬁcation (Table 2), which is much higher than that with the
reported primers, which could not detect two of seven geno-
types and ampliﬁed only 14/69 subtypes with 79.8% sensitivity
(Table 2) [30].
The ampliﬁcation rate for each primer pair for each subtype
of HCV is shown on Table 2. The overall percentage of each
pair of primers is shown at the bottom of Table 2. Based on the
ampliﬁed size and sensitivity of each primer pair, two primer
pairs (red) were selected: F1/R2, whose ampliﬁcation rate and
size were 96.45% and 691 bp, and F2/R3, 94.59% and 825 bp.
Moreover, if the subtypes of the two pairs of primers failed to
amplify, for example, subtype 3b and 3c on Table 2, another
two pairs of primers (F2/R2 or F3/R3) were able to amplify
them as compensation (Table 2). These data indicate that a
combination of PCR ampliﬁcation with the four pairs of PCR
primers (F1/R2. F2/R3, F2/R2 and F3/R3) could amplify all of six
HCV subtypes (1117/1127) with high sensitivity for
ampliﬁcation.
Determination of known standard HCV genotypes by
sequencing NS5B region with the new primers
The cDNAs from ﬁve known standard HCV subtypes, i.e. HCV
1a, 2a, 3b, 6a and 1b, were ampliﬁed with the ten primer pairs
by RT-PCR and analysed by DNA gel electrophoresis (Fig. 4a),ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
FIG. 2. Phylogenetic analysis of the genetic relatedness with different sequences of NS5B regions. (a) Phylogenetic analysis of the genetic relatedness in
32 of the nucleic acid sequences of hepatitis C virus (HCV) subtypes from the NIB database with the 8370–8708 or 8323–8638 NS5B region. (b)
Phylogenetic analysis of the genetic relatedness in 32 sequences of HCV subtypes with full-length NS5B. (c) Phylogenetic analysis of the genetic
relatedness in 1127 sequences of HCV subtypes with full-length NS5B.
CMI Tong et al. Accurate genotyping of HCV through new NS5B regions 874.e14and showed a clear band with correct size and without any non-
speciﬁc bands for each primer pair; the DNA fragments were
then extracted from the gel and sequenced (Fig. 4b). The
resulting sequences were mapped against the HCV database
(http://www.ncbi.nlm.nih.gov/projects/genotyping), whichClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infshowed that they are fully mapped to the correct HCV subtype
(red part) (Fig. 4c). Phylogenetic analysis showed that the
location of the standard NS5B sequences ampliﬁed by the
primers were in the same cluster as the standard HCV stains
(HCV 1a, 2a, 3b, 6a and 1b) belong to, which is indicated by aectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
FIG. 3. Primer design and possibility for ampliﬁcation of NS5B. (a, b) The potential forward (a) and reverse (b) primers for amplifying NS5B region of
hepatitis C virus (HCV). Each row represents a NS5B nucleotide sequence, and each image pixel represents a base. The pixel grey-scale represents the
weight of the PCR primer cluster located in NS5B region. The weight increased when the bases located in the PCR primer cluster. The deep colour
region means that the region can be ampliﬁed with the PCR primers at a high ampliﬁcation capacity across the whole HCV population. To clearly
display pictures, the threshold value was set at 500 dpi, and the pixels were set as white colour when they were lower than the threshold. (c) Location
of the potential primers in NS5B region.
874.e15 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIred arrow in Fig. 4d. These data indicate that the predicted
primers can speciﬁcally and correctly identify the standard HCV
subtypes.
Detection of HCV in clinical samples by sequencing
NS5B region ampliﬁed with the new primers
A total of 567 patients with HCV in the Hubei province region
of China were analysed for HCV subtype by sequencing analysis
using the PCR products ampliﬁed with the ten primer pairs.
Fig. 5a showed the representative bands of the PCR products
ampliﬁed with these primers for HCV 1b-2a. The resulting PCR
products were sequenced and mapped to the HCV database.
Fig. 5b is a representative result, which showed the clear
sequencing and Fig. 5c showed the mapping data for HCV
1b–2a subtype. We also analysed the ampliﬁcation sensitivity of
each primer pair in patient samples, and found that the NS5B
fragments were ampliﬁed by each of the ten primer pairs with aClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecthigh sensitivity (92.59–98.59%) (Table 3). Importantly, three
new HCV subtypes (1b-2a, 1b-2K and 6d-6k) were detected in
our samples that have not been previously reported in China
(Table 3). We further found that the detection rate for HCV
subtypes in the patients with the method, was 100%. Even the
combination of only two pairs (F1/R2 and F2/R3) could amplify
almost all the patient samples and if combined with another two
pairs of primers (F2/R2 and F3/R3), they could amplify all the
patients’ samples (Table 3). These data suggested that the four
pairs of primers are efﬁcient enough for clinical subtyping of the
HCV samples. We analysed the distribution ratio of the HCV
subtypes in the population, and found that HCV 1b accounted
for 60.3% (342/567) in the HCV patients, followed by HCV 3b
and 2a, accounted for 12.0% (68/567) and 9.3% (53/567),
respectively (Fig. 5d). However, the HCV 1b had a larger
proportion in the previously reported Chinese population,
which accounted for 41.8% (1074/2568), ranked the ﬁrst; HCVious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
TABLE 2. The theoretical ampliﬁcation ability of the potential primers for all NS5B from hepatitis C virus (HCV) database
HCV subtype
No.
(n = 1127)
Primers (ampliﬁcation length)
F1-R1
(328 bp)
F1-R2
(691 bp)
F1-R3
(1137 bp)
F1-R4
(1275 bp)
F2-R2
(379 bp)
F2-R3
(825 bp)
F2-R4
(963 bp)
F3-R3
(472 bp)
F3-R4
(610 bp)
F4-R4
(162 bp)
Reported [31]
(339 bp)
1a 438 100.00% 97.95% 97.26% 87.67% 97.95% 97.26% 87.67% 97.26% 87.67% 87.67% 89.50%
1a-1b 6 100.00% 100.00% 100.00% 50.00% 100.00% 100.00% 50.00% 100.00% 50.00% 50.00% 100.00%
1a-2a 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
1b 355 97.75% 96.62% 96.06% 95.21% 98.03% 97.46% 96.34% 97.46% 96.34% 96.90% 83.66%
1b-2k 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
1c 3 100.00% 66.67% 100.00% 100.00% 66.67% 100.00% 100.00% 100.00% 100.00% 100.00% 66.67%
1g 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
VAR_1a 29 100.00% 96.55% 96.55% 75.86% 96.55% 96.55% 75.86% 96.55% 75.86% 75.86% 79.31%
VAR_1a_2a 4 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
VAR_1b 87 97.70% 100.00% 96.55% 96.55% 100.00% 96.55% 96.55% 96.55% 96.55% 96.55% 93.10%
VAR_1c 2 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
2a 19 100.00% 94.74% 100.00% 100.00% 84.21% 89.47% 89.47% 100.00% 100.00% 100.00% 78.95%
2b 25 96.00% 84.00% 88.00% 88.00% 88.00% 92.00% 92.00% 92.00% 92.00% 92.00% 80.00%
2b-1b 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
2c 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
2i 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
2i_6p 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
2k 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
VAR_2a 45 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 11.11%
3a 8 0 0 0 0 87.50% 62.50% 37.50% 62.50% 37.50% 25.00% 87.50%
3b 1 0 0 0 0 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
3c 1 0 0 0 0 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
VAR_3b 3 0 0 0 0 100.00% 0 0 0 0 0 100.00%
4a 16 100.00% 100.00% 87.50% 56.25% 100.00% 87.50% 56.25% 87.50% 56.25% 56.25% 100.00%
4b 3 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
4d 3 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
4f 6 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
4k 2 100.00% 100.00% 100.00% 0 100.00% 100.00% 0 100.00% 0 0 100.00%
5a 3 33.33% 33.33% 33.33% 33.33% 33.33% 66.67% 66.67% 100.00% 100.00% 100.00% 33.33%
6a 16 93.75% 100.00% 100.00% 100.00% 12.50% 12.50% 12.50% 100.00% 100.00% 100.00% 0
6b 1 100.00% 0 100.00% 100.00% 0 0 0 0 0 100.00% 0
6c 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
6d 1 100.00% 100.00% 100.00% 100.00% 0 0 0 100.00% 100.00% 100.00% 0
6e 4 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 50.00%
6f 3 33.33% 100.00% 100.00% 0 66.67% 66.67% 0 100.00% 0 0 0
6g 3 100.00% 100.00% 100.00% 100.00% 66.67% 66.67% 66.67% 100.00% 100.00% 100.00% 33.33%
6h 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
6i 3 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
6j 2 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
6k 5 20.00% 20.00% 20.00% 20.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
6l 2 0 0 0 0 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 50.00%
6m 4 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
6n 5 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 20.00%
6o 2 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0
6p 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
6q 1 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
6t 4 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
7a 1 0 0 0 0 0 0 0 0 0 100.00% 0
Overall 1127 96.45% 95.12% 94.59% 88.91% 95.56% 94.59% 88.73% 96.36% 90.42% 90.68% 79.86%
CMI Tong et al. Accurate genotyping of HCV through new NS5B regions 874.e163b (12.5%) and 2a (10.2%) ranked third and fourth, respectively
(Fig. 5e). HCV 6a subtype accounted for 18.0% in the reported
Chinese population (462/2568), ranked the second, but it only
ranked the fourth (2.1%) in our samples, far lower than that in
the reported. The detective rate for new HCV subtypes in the
samples was HCV 1b-2a 2.8%, 1b-2k 2.1%, and 6d-6k 2.3%
(Fig. 5D). These data indicates this method is more sensitive for
subtyping of clinical HCV samples.Discussion and conclusionsThere are many methods for classifying HCV by analysis of
certain regions of the virus based on the length and diversity of
the HCV genome; however, the protocols still lackClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infstandardization [31]. Here, we developed a more accurate and
more reliable method for genotyping HCV by sequencing NS5B
regions ampliﬁed with the primer pair from the eight identiﬁed
primers. This method has higher sensitivity for ampliﬁcation and
100% sensitivity for subtyping of clinical HCV samples.
Sequence analysis of NS5B for genotyping HCV provides
precise genotype and subtype identiﬁcation and an accurate
epidemiological representation of circulating viral strains.
However, current HCV NS5B-based genotyping uses only
partial short nucleic acid sequences of NS5B. Koletzki et al. [32]
used a 329-bp NS5B gene fragment (nucleotides 8280–8610 in
HCV sequence) to classify HCV and showed an 89% clinical
sensitivity for ampliﬁcation. Cantaloube et al. [30] used 339-bp
nucleotide segments (nucleotides 8370–8708) in the NS5B
region to classify HCV and achieved a 98.32% of sensitivity forectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
FIG. 4. Ampliﬁcation of the standard hepatitis C virus (HCV) subtypes with the predicted primers. (a) Gel electrophoresis after PCR ampliﬁcation of
HCV 1b and 2a. (b) Sequencing results of the PCR products of HCV 1b and 2a. (c) Mapping the HCV 1b and 2a sequences with the HCV database. The
red part indicates that they are fully aligned. (d) Phylogenetic analysis of the HCV 1b and 2a sequences and their location in phylogenetic tree of
standard HCV stains HCV 1a, 2a, 3b, 6a and 1b (see the red arrow) using CLUSTALW2 software.
874.e17 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIampliﬁcation; however, they only detected HCV type 4 and 1.
Murphy et al. [33] used primers located in the NS5B gene
(nucleotide 8323–8638) to classify HCV and reached a 97.3%
sensitivity for ampliﬁcation with many random primers. How-
ever, our study showed that it could not distinguish between
subtype 5 and 1 or between 4 and 5 if only sequencing the
reported nucleotide segment (nucleotide 8370–8708 or
8323–8638) in the NS5B region (Fig. 2a). Our method here is
designed to sequence NS5B region ampliﬁed with only eight
primers, which has theoretically 99.20% (1117/1127) sensitivity
for ampliﬁcation, and is able to detect six of seven genotypes of
HCV, and even reach 100% sensitivity for HCV subtyping in our
observed clinical samples.
The major characteristic of our method is the use of a com-
puter tool to search for the best primers for sequencing the
NS5B region using the entire NS5B sequence from all 1127 HCV
genomic DNAs and the eight best primers. The computer tool is
also used to examine the possibility of ampliﬁcation using the ten
primer pairs and it found that four primer pairs (F1/R2, F2/R3,
F2/R2 and F3/R3) could amplify all the available HCV genomicClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectsequences in six of seven HCV genotypes. Our result also
showed that this method could detect the ﬁve known standard
HCV subtypes with 100% accuracy. More importantly, this
method could detect the subtypes of all 567 clinical HCV samples
with almost 100% sensitivity and even only using the four pairs of
primers (F1/R2, F2/R3, F2/R2 and F3/R3). Of course, the best
genotyping method is sequencing the whole HCV genome;
however, this is not applicable for clinical samples. Our results
indicated that sequencing the ampliﬁed NS5B region with our
identiﬁed primers is a reliable, sensitive and economical method
for clinical genotyping and subtyping of the HCV.
Correctly genotyping and subtyping HCV is critical for clin-
ical diagnosis and treatment of HCV, and also HCV classiﬁcation
and epidemiology studies [34]. Our subtyping data showed that
the subtypes of HCV 1b, 2a, 3b and 6a, accounted for 60.35%,
9.3%, 12.0% and 2.1%, respectively in our observed patient
samples, whereas the frequency of HCV subtyping in the pre-
viously reported Chinese population (2010), HCV 1b, 2a, 3b
and 6a, accounted for 41.8%, 10.2%, 12.5% and 18.0%,
respectively. The percentage of HCV 1b in our samples is muchious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
FIG. 5. Distribution of the hepatitis C virus (HCV) genotypes identiﬁed in the HCV patients. (a) Gel electrophoresis after PCR ampliﬁcation of HCV
1b-2a. (b) Sequencing results of the PCR products of HCV 1b-2a. (c) Mapping the HCV 1b-2a sequence with the HCV database. (d) Percentage of HCV
genotypes identiﬁed in the population of Hubei province of China. (e) Percentage of HCV genotypes identiﬁed in all Chinese population from the HCV
database.
CMI Tong et al. Accurate genotyping of HCV through new NS5B regions 874.e18higher than previously reported. We also compared the prev-
alence of our HCV genotypes with that of worldwide reports.
Recently, Gower et al. [35] and Messina et al. [36] reported that
HCV genotype 1 was the most common (46% or 46.2%) in
HCV patients of 87 or 117 countries, followed by genotype 3
(22% and 30.1%). Both genotype 2 and 4 occupied 13% in
Gower et al.’s report and Messina et al. also observedClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infgenotypes 2, 4 and 6 responsible for a total 22.8% of all cases
[35,36]. Our data showed that the genotype 1 (1b + 1a) is
dominant genotype of HCV in China, as worldwide, occupied
61.9% (60.3 + 1.6%) of total patients in the cohort, followed by
genotype 3 (3b, 12%), genotype 6 (6a + 6b, 9.5%) and genotype
2 (2a, 9.3%). These data also showed a higher rate for genotype
1 (mainly 1b) than that found in worldwide reports.ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 874.e9–874.e21
TABLE 3. The ampliﬁcation ability of the potential primers for 567 patients with hepatitis C virus (HCV)
HCV subtype
No.
(n = 567)
Primers (ampliﬁcation length)
F1-R1
(328 bp)
F1-R2
(691 bp)
F1-R3
(1137 bp)
F1-R4
(1275 bp)
F2-R2
(379 bp)
F2-R3
(825 bp)
F2-R4
(963 bp)
F3-R3
(472 bp)
F3-R4
(610 bp)
F4-R4
(162 bp)
1a 9 100.00% 100.00% 88.89% 88.89% 100% 100.00% 77.78% 77.78% 66.7% 66.67%
1b 342 97.66% 97.66% 97.37% 97.95% 98.54% 99.71% 92.40% 96.78% 94.74% 90.94%
1b-2k 12 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
2a 53 100.00% 92.45% 100.00% 100.00% 94.34% 98.11% 90.57% 100.00% 100.00% 100.00%
3b 68 97.06% 86.76% 91.18% 77.94% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
6b 42 100.00% 100.00% 100.00% 100.00% 88.10% 85.71% 78.57% 90.48% 92.65% 100.00%
1b-2a 16 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
6d-6k 13 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
6a 12 91.67% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Overall Sensitivity 98.06% 96.30% 97.19% 95.94%6 97.71% 98.59% 92.59% 97.00% 95.41% 94.00%
874.e19 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIHepatitis C virus genotype 1b was reported to be associated
with progression to chronicity, cirrhosis, and severe and
decompensated liver disease [37,38]; also rapid recurrence and
severe hepatitis in transplant patients when compared with the
other HCV genotypes [39]. A linkage of HCV 1b with the fre-
quency and development of HCC was also reported [40–43].
These studies suggested that genotype 1b is a potential marker
for more severe HCV-associated liver disease. We observed an
increase of HCV 1b, which not only suggested the sensitivity
increase of our method, but also suggested an increase of HCV-
infection-associated severe liver disease in China.
Moreover, Petruzziello et al. [44] reported that the rate of
genotype 1 in Italy occupied 63.6% of total HCV cases, followed
by genotype 2 (29.4%), genotype 3 (6.2%) and genotype 4 (0.8%).
They also found that subtype 1b was more frequent in females
than in males. Conversely, genotype 3 was more frequent in
males [44]. The reported rate of genotypes 1 and 3 is similar to
that of our data. However, the percentage of genotype 2 is much
higher than our data; also we did not observe the sex difference
of genotypes 1b and 3 in our cohort (data not shown).
Hepatitis C virus genotype 6 (HCV 6) is restricted to South
China, South East Asia, and is also occasionally found in migrant
patients from endemic countries. HCV 6 has considerable ge-
netic diversity with 23 subtypes (a to w) [45]. Our data showed
that the frequency of HCV 6a is dramatically reduced in our
observed samples compared with previous reports (Table 2).
The reason for this difference may be because our sequencing
method is more speciﬁc and more reliable for subtyping, which
prevents other subtypes also mistakenly classifying as HCV 6a.
We did not detect genotypes 4 and 5, which have the largest
proportions in lower-income areas. Instead, we identiﬁed three
new HCV subtypes 1b-2a, 1b-2k and 6d-6k. HCV was thought
to evolve in a clonal manner, with diversity generated through
the accumulation of mutations. However, several events of
inter- and intragenotypic homologous recombination (1a-1b,
1a-1c, 2b-1b, 2k-1b, 2-5, 1b-1a, 2i-6h) have been reported to
date from different regions of the world [46–48]. We believeClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthat the identiﬁed new subtypes result from putative inter- and
intragenotypic recombination. Also, the recombination events
were detected in 25 of the 234 independent samples analysed
(10.7%) [49]. We observed that the detection rates for the new
subtypes were HCV 1b-2a 2.8%, 1b-2k 2.1% and 6d-6k 2.3% in
the NS5A region, which is lower than the reports. Only a few
studies have reported the recombination in natural populations
of HCV [49]. Our study is the ﬁrst report of the putative
recombination of HCV in Chinese patients. The recombination
is considered as a potentially relevant mechanism generating
genetic variation in HCV with important implications for the
treatment of this infection [49]. Unfortunately, most of the
HCV-infected patients in this study were outpatients. Detailed
clinical data for the new HCV subtypes were lacking. Patients in
this study included those with acute hepatitis C, chronic hep-
atitis C, hepatitis C cirrhosis and HCV acute exacerbation. We
are unable to make a deﬁnite correlation between the new
HCV subtypes and a speciﬁc appearance of clinical conditions;
however, we believe that the new HCV subtypes may appear
mainly in the patients with severe hepatitis or acute exacer-
bation and reactivation of chronic HCV infection or HCC
development; and the clinical signiﬁcance of the new HCV
subtypes will be further clariﬁed.
In conclusion, the new NS5B regions ampliﬁed with the
newly designed primers can be used to genotype HCV with high
sensitivity for ampliﬁcation, higher accuracy and 100% sensi-
tivity for subtyping clinical HCV samples. With this method, we
observed changes in the ratio of HCV subtypes and identiﬁed
new HCV subtypes, which is helpful for clinical diagnosis,
treatment, classiﬁcation of HCV infection and the study of HCV
epidemiology and vaccine development.Transparency declarationAll authors report that there are no conﬂicts of interest. All
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